Skip Navigation

European Journal of Heart Failure 2001 3(3):265-269; doi:10.1016/S1388-9842(01)00140-4
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Isnard, R.
Right arrow Articles by Komajda, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isnard, R.
Right arrow Articles by Komajda, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

Thromboembolism in heart failure, old ideas and new challenges

Richard Isnard* and Michel Komajda

Cardiology Department, Hôpital Pitié-Salpêtrière 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France

* Corresponding author. IFR 14 ‘Muscles, cœur, vaisseaux’. Tel.: +33-142176727; fax: +33-142176719 E-mail address: richard.isnard{at}psl.ap-hop-paris.fr ((R. Isnard).


  Abstract

Until now, the administration of antithrombotic therapy in patients with congestive heart failure has not been well codified. The incidence of thromboembolic complication, such as stroke, peripheral or pulmonary embolism, is regarded as too low to justify the use of anticoagulation in non-selected patients. However, other thrombotic complications may occur especially in patients with ischemic heart failure and represent potential targets for antithrombotic therapy. The objective of this paper is to review the available evidence in the absence of the results of large ongoing trials.

Key Words: Congestive heart failure • Anticoagulation • Antithrombotic therapy

Received August 2, 2000; Revised December 22, 2000; Accepted February 12, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.